Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies

Event Details

Background

Urologic Chronic Pelvic Pain Syndrome (UCPPS) encompasses both Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). UCPPS is defined by the hallmark symptom of chronic pain in the pelvis, urogenital floor, and/or external genitalia often accompanied by diverse urologic symptoms, such as urgency and frequency. UCPPS is highly prevalent and its impact on patients’ quality of life is enormous. However, despite much past research broadly effective clinical management strategies are still lacking.

Meeting Objectives

The Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies meeting will provide a forum for exchange of new insights into UCPPS underlying mechanisms and clinical characteristics. The meeting will highlight findings from the NIDDK’s Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network and other investigators working in the UCPPS field, as well as advances in other areas that may inform the study of UCPPS. Collectively these efforts are providing a critical new evidence base to support future studies of UCPPS, including improved clinical trial designs.

Major scientific themes will include:

• Phenotypic Subgrouping Strategies for Targeted Interventions
• Mechanistic Insights in Support of New Targets and Phenotypes
• Improved Evidence-Based Definitions and Outcome Measures
• Designs for Clinical Trials Informed by New Research Insights

Breakout groups for these themes will support discussion of key considerations for potential future UCPPS clinical trials. In addition, a novel Patient Forum will be convened to solicit input from the patient perspective.

A central goal of the meeting is to promote the translation of new findings into future, evidence-based clinical trials for UCPPS that will ultimately improve patient care.

Planning Committee:
Chris Mullins, Ph.D.
Julie Barthold, M.D.
Kasey Boehmer, Ph.D., M.P.H.
Toby Chai, M.D.
J. Quentin Clemens, M.D.
Ziya Kirkali, M.D.
Robert Moldwin, M.D.

Registration Deadline

October 10, 2022

Abstract Deadline

October 6, 2022

Agenda

Speaker order within sessions and times subject to change.

October 17, 2022

8:30 a.m. – 8:50 a.m.

Welcome and Meeting Overview
Robert Star, M.D., NIDDK
Chris Mullins, Ph.D., NIDDK

8:50 a.m. – 9:30 a.m.

Plenary Presentation: State of the Urologic Chronic Pelvic Pain Syndrome (UCPPS) Field: Where We’ve Been and Where We Need to Go…
Quentin Clemens, M.D., University of Michigan

9:30 a.m. – 10:30 a.m.

UCPPS Patient Forum
Moderator: Kasey Boehmer, Ph.D., M.P.H., Mayo Clinic

10:30 a.m. – 10:50 a.m.

Morning Break

10:50 a.m. – 12:30 p.m.

Scientific Session I: Phenotypic Subgrouping Strategies for Targeted Intervention
Moderator: Robert Moldwin, M.D., Hofstra-Northwell
(Talks: 15 minutes + 5-minute Q&A)

10:50 a.m. – 11:10 a.m.

• Clinical Phenotyping of IC/BPS – A Big Picture from 30,000 Ft
  Henry Lai, M.D., Washington University in St. Louis

11:10 a.m. – 11:30 a.m.

• A Two-Dimensional Assessment System for Symptom Severity in Urological Chronic Pelvic Pain Syndromes
  Bruce Naliboff, Ph.D., University of California, Los Angeles

11:30 a.m. – 11:50 a.m.

• Leveraging Molecular and Clinical Data for Patient Stratification in Interstitial Cystitis/Bladder Pain Syndrome
  Stephen Walker, Ph.D., Wake Forest University School of Medicine

11:50 a.m.  – 12:10 p.m.

• Clinical Sub-Phenotypes for UCPPS: About the Hunner lesion
  Magnus Fall, Ph.D., University of Gothenburg, Sweden

12:10 p.m. – 12:30 p.m.

• Painful Temporomandibular Disorders: A Phenotype Revolving Around Self-Reported Symptoms
  Richard Ohrbach, Ph.D., University of Buffalo

12:30 p.m. – 12:50 p.m.

Moderated Discussion: UCPPS Phenotypic Subgrouping Strategies for Targeted Intervention
Moderator: Robert Moldwin, M.D., Hofstra-Northwell

12:50 p.m. – 1:35 p.m.

Lunch

1:35 p.m. – 1:50 p.m.

Virtual Poster “Flash Talks”

• What is the Optimal Technique for Hydrodistention? First Randomized Trial Studying Hydrodistention Parameters for IC/BPS
  Alex Zhu, DO; University of Michigan

• Gene Expression Profiles of Bladder Mucosa Stratifies IC/BPS Patients Based on Anesthetized Bladder Capacity
  Max Sandberg, M.D.; Wake Forest University

• Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy for Pelvic Pain Reduction and Symptom Improvement in IC/BPS: A Pilot Study Gene
  Wyatt Whitman, M.D.; Wake Forest University

1:50 p.m. – 3:30 p.m.

Scientific Session II: Mechanistic Insights in Support of New Targets and Phenotypes
Moderator: Toby Chai, M.D., Boston University
(Talks: 15 minutes + 5-minute Q&A)

1:50 p.m. – 2:10 p.m.

• Neuroimaging in MAPP: Insights into Disease and Uncovering New Treatment Targets
  Jason Kutch, Ph.D., University of Southern California

2:10 p.m. – 2:30 p.m.

• Immunoreactivity in Female IC/BPS Patients is Associated with the Nociplastic Pain Mechanism: Evidence and Clinical Implications
  Andrew Schrepf, Ph.D., University of Michigan

2:30 p.m. – 2:50 p.m.

• The Microbiome, the Proteome, and Diet
  Jennifer Anger, M.D., University of California, San Diego

2:50 p.m. – 3:10 p.m.

• Pelvic Floor Tenderness in UCPPS: Implications for Phenyotyping and Therapy
  Priyanka Gupta, M.D., University of Michigan

3:10 p.m. – 3:30 p.m.

• Pelvic Origins of UCPPS, A Uterine Explanation?
  Frank Tu, M.D., M.P.H., NorthShore University HealthSystem and the University of Chicago

3:30 p.m. –  3:50 p.m.

Moderated Discussion: Mechanistic Insights in Support of New Targets and Phenotypes for UCPPS
Moderator: Toby Chai, M.D., Boston University

3:50 p.m. – 4:00 p.m.

Break

4:00 p.m. – 5:00 p.m.

Breakout Groups: Begin Discussions of Key Concepts for Potential Future UCPPS Clinical Trials

• UCPPS Phenotypic Subgrouping Strategies for Targeted Intervention
• Mechanistic Insights in Support of New Targets and Phenotypes for UCPPS
• Improved Evidence-based Outcome Measures for UCPPS
• Designs for Potential Future UCPPS Clinical Trials Informed by New Research Insights

5:00 p.m. – 5:20 p.m.

Reports from Breakout Discussions

5:20 p.m.

Adjournment

October 18, 2022

8:30 a.m. – 8:40 a.m.

Welcome and Plans for Day 2
NIDDK

8:40 a.m. – 10:00 a.m.

Scientific Session III: Improved Evidence-based Definitions and Outcome Measures
Moderator: Quentin Clemens, M.D.; University of Michigan
(Talks: 15 minutes + 5-minute Q&A)

8:40 a.m. – 9:00 a.m.

• Which 'Better' is Best? A Heterogeneity-Aware Case for Clinically Important Differences in UCPPS
  Alisa Stephens-Shield, Ph.D., University of Pennsylvania

9:00 a.m. – 9:20 a.m.

• Future Directions in Clinical Assessment
  Jamie Griffith, Ph.D., Northwestern University

9:20 a.m. – 9:40 a.m.

• UCPPS Symptom Flares: A Possible New Outcome Measure for UCPPS Research
  Siobhan Sutcliffe, Ph.D., Washington University in St. Louis

9:40 a.m. – 10:00 a.m.

• Two Methods of Classifying Chronic Overlapping Pain Conditions (COPCs)
  David Williams, Ph.D., University of Michigan

10:00 a.m. – 10:20 a.m.

Break

10:20 a.m. – 10:40 a.m.

Moderated Discussion: Improved Evidence-based Definitions and Outcome Measures for UCPPS
Moderator: Quentin Clemens, M.D., University of Michigan

10:40 a.m. – 11:30 a.m.

Measures, Tools, and Resources: Promoting New UCPPS Studies
Quentin Clemens, M.D.; University of Michigan
J. Richard Landis, Ph.D.; University of Pennsylvania
Chris Mullins, Ph.D.; NIDDK

11:30 a.m. – 12:30 p.m.

Lunch

12:00 p.m. – 12:30 p.m.

Special Breakout Room for “DataView Tutorial”
J. Richard Landis, Ph.D.; University of Pennsylvania

12:30 p.m. – 2:10 p.m.

Scientific Session IV: Designs for Clinical Trials Informed by New Research Insights
Moderator: Henry Lai, M.D., Washington University in St. Louis
(Talks: 15 minutes + 5-minute Q&A)

12:30 p.m. – 12:50 p.m.

• Using SMART Designs to Apply A Precision Medicine Approach to Chronic Pain
  Daniel Clauw, M.D., University of Michigan

12:50 p.m. – 1:10 p.m.

• Rationale, Design, and Lessons Learned from the UPDATe Study: A Multicenter RCT of Vestibulodynia
  Andrea Nackley, Ph.D., Duke University

1:10 p.m. – 1:30 p.m.

• Enriching Clinical Trials Through NEPTUNE-Match
  Debbie S. Gipson, M.D., University of Michigan

1:30 p.m. – 1:50 p.m.

• Adaptive Platform Trials: Innovation in Clinical Trial Design
  Ben Saville, Ph.D., Vanderbilt University

1:50 p.m. – 2:10 p.m.

• Best Practices in Recruitment, Engagement, and Retention
  Marissa Reynolds, Massachusetts General Hospital

2:10 p.m. – 2:30 p.m.

Moderated Discussion: Designs for Potential Future UCPPS Clinical Trials Informed by New Research Insights
Moderator: Henry Lai, M.D., Washington University in St. Louis

2:30 p.m. – 2:50 p.m.

Break

2:50 p.m. – 3:40 p.m.

Breakout Groups: Discuss and Summarize Key Concepts for Potential Future UCPPS Trials

• UCPPS Phenotypic Subgrouping Strategies for Targeted Intervention
• Mechanistic Insights in Support of New Targets and Phenotypes for UCPPS
• Improved Evidence-based Definitions and Outcome Measures for UCPPS
• Designs for Potential Future UCPPS Clinical Trials Informed by New Research Insights

3:40 p.m. – 4:20 p.m.

Reports from Breakout Discussions

4:20 p.m. – 4:30 p.m.

Final Patient Comments
Patients

4:30 p.m. – 5:15 p.m.

Pulling It Together
NIDDK

5:15 p.m. – 5:25 p.m.

National Institutes of Health Remarks and Adjournment
NIDDK

5:25 p.m.

Adjourn

Abstracts

Attendees are invited to submit abstracts for virtual poster presentations. Any attendee may submit an abstract for a possible virtual presentation, but we especially encourage young/junior and early stage investigators and trainees to submit their work. Submitted Abstracts may represent a broad scope of work relevant to the study of UCPPS. We ask that all abstracts and/or presentations note the potential for the work to add to an evidence-base supporting new and improved clinical studies and trials for UCPPS.

Please note, space may be limited, and the organizing committee may implement a selection process. Further information regarding these talks will be provided to presenters approximately two weeks before the meeting.

Submission Deadline

October 6, 2022

Submitting Abstracts

All abstracts must be submitted via email to Danielle Johnikin, with “Abstract-NIDDK Research Advances” in the subject line. The abstract submission should be a 1-page Microsoft Word document that does not exceed 250 words (not including the abstract’s title and name and affiliation of all authors).

Presenters are welcome to present abstracts previously-presented in other venues.

Download the Abstract Template (DOCX, 24.67 KB) .

Abstract Organization

Organize the body of the abstract as follows:

• Statement of the study’s purpose
• Statement of the methods used
• Summary of the results presented in sufficient detail to support the conclusion
• Statement of the conclusions reached

Formatting Requirements

Please follow the instructions below to format an abstract. (Note: Submissions will not be edited for spelling or grammar and will be accepted “as is.”)

• The abstract should be a Microsoft Word document with 1-inch margins, typed single space, using Times New Roman font; a 12-point font should be used for everything except the title.
• The abstract’s title should be Typed in Title Case using Bold 16-Point font, and it should clearly represent the nature of the investigation. Do not use subheadings (e.g., Methods, Results) in the body of the abstract.
• Skip one line after the title, and list the author’s first and last names, degree, affiliation, city, state, and country. Separate multiple authors with a semicolon, and underline the primary author’s name (one primary author per abstract).
• Use one blank line between the title and the authors, the authors and the body of the abstract, and between paragraphs.
• Please ensure that your abstract is the correct length (no longer than 250 words).
• Use standard abbreviations (e.g., RBC) and standard symbols for units of measure (e.g., kg, g, mg, mL, L, and %). Place abbreviations and acronyms in parentheses after the full word the first time that the term appears. Use numerals to indicate numbers, except as the first word of a sentence.
• Simple tables or graphs may be included; however, the abstract may not be longer than one page, including any tables or graphs